Salbutamol-containing ophthalmic medicament

A composition, characterized in that it comprises or consists essentially of, or consists of:

• Salbutamol or a pharmaceutically acceptable salt thereof, and
• One or several active principle(s) selected from the group consisting of:
• beta 1 adrenergic blockers, alpha 2 adrenergic agonists, anhydrase carbonic inhibitors, angiotensin converting enzyme inhibitors, aldosterone receptor antagonist, N Acetyl Leucine, glucose, magnesium, potassium, nitric monoxide donors, steroidal anti inflammatory drugs, non steroidal anti inflammatory drugs, proteolytic enzyme, one of their pharmaceutically acceptable salts thereof, and mixtures thereof, and
• Optionally, pharmaceutically acceptable additive(s), diluent(s) or vehicle(s) or carrier(s).

A kit of parts of a first active principle that is Salbutamol or a pharmaceutically acceptable salt thereof, with one or more active principle(s) selected from the group consisting of:

• beta 1 adrenergic blockers, alpha 2 adrenergic agonists, anhydrase carbonic inhibitors, angiotensin converting enzyme inhibitors, aldosterone receptor antagonist, N Acetyl DL Leucine, glucose, magnesium, potassium, nitric monoxide donors, steroidal anti inflammatory drugs, non steroidal anti inflammatory drugs, proteolytic enzyme, one of their pharmaceutically acceptable salts thereof, the active principle(s) being found in admixture or separately, wherein said active principles are capable of jointly preventing and/or treating of one or several ophthalmic disease(s) involving a deterioration of the eye and/or of the visual function, wherein said ophthalmic disease(s) is(are) selected from the group comprising:
• hereditary dystrophies of the retina, glaucoma, glaucoma neuropathy, age related macular degeneration, ametropia, dry eye, hereditary dystrophies of ocular inflammation, ocular inflammation, uveitis, orbital inflammation, cataract, allergic conjunctivitis, diabetic retinopathy, macular oedema, corneal oedema, keratoconus, proliferative vitreo retinopathy (fibrosis), peri-retinal fibrosis, central serious chorio retinopathy, vitreo retinal pathology, vitreo macular traction and vitreous hemorrhage, and/or jointly maintaining or improving the visual function.

A kit comprising or consisting essentially of or consisting of:

• At least two active principles selected from the group consisting of:
• salbutamol, beta 1 adrenergic blockers, alpha 2 adrenergic agonists, anhydrase carbonic inhibitors, angiotensin converting enzyme inhibitors, aldosterone receptor antagonist, N Acetyl DL Leucine, glucose, magnesium, potassium, nitric monoxide donors, steroidal anti inflammatory drugs, non steroidal anti inflammatory drugs, proteolytic enzyme, one of their pharmaceutically acceptable salts thereof, and
• Optionally, instructions for using said kit,
• wherein said active principles are associated in a same composition or wherein at least two or more of these active principles are in separate compositions.